

**John J. Castellani**

President & Chief Executive Officer

June 25, 2015

The Honorable John Boehner  
Speaker  
U.S. House of Representatives  
H-232, The Capitol  
Washington, DC 20515

The Honorable Nancy Pelosi  
Minority Leader  
U.S. House of Representatives  
H-204, The Capitol  
Washington, DC 20515

The Honorable Fred Upton  
Chairman  
Energy and Commerce Committee  
U.S. House of Representatives  
2125 Rayburn House Office Building  
Washington, DC 20515

The Honorable Frank Pallone  
Ranking Member  
Energy and Commerce Committee  
U.S. House of Representatives  
2322A Rayburn House Office Building  
Washington, DC 20515

Dear Speaker Boehner, Leader Pelosi, Chairman Upton and Ranking Member Pallone:

On behalf of the Pharmaceutical Research and Manufacturers of America (PhRMA), I am writing to express our support for H.R. 1725, the "National All-Schedules Electronic Reporting (NASPER) Reauthorization Act of 2015." PhRMA and our members companies share your commitment to ensuring the appropriate use of prescription medicines and addressing the diversion, misuse, and abuse of prescription medicines. The NASPER program is critical to strengthening state efforts to combat prescription drug abuse.

We are pleased that H.R. 1725 would reauthorize the NASPER program through 2020 and urge swift passage of this legislation. We look forward to continuing to work with you and other leaders in Congress to address the misuse and abuse of prescription medicines. Thank you for your attention to this important matter.

Sincerely,

